Synergistic pharmaceutical combination for the treatment of cancer

A pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin, and gemcitabine or a pharmaceutically acceptable salt thereof;

• and a CDK inhibitor or an enantiomer or a pharmaceutically acceptable salt or solvate thereof, wherein said CDK inhibitor is represented by the following formula I;
• wherein Ar is phenyl, which is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from:
• halogen selected from chlorine, bromine, fluorine or iodine, nitro, cyano, C1-C4-alkyl, trifluoromethyl, hydroxyl, C1-C4-alkoxy, carboxy, C1-C4-alkoxycarbonyl, CONH2, and NR1R2;
• wherein R1 and R2 are each independently selected from hydrogen or C1-C4-alkyl.